摘要
目的观察甲钴胺联合前列地尔治疗糖尿病周围神经病变(DPN)的临床疗效和安全性,并探讨其作用机制。方法将94例DPN患者随机分为对照组47例和试验组47例。在常规治疗的基础上,对照组给予以前列地尔注射液10μg,每日1次,静脉注射;试验组予以前列地尔注射液10μg,每日1次,静脉注射+甲钴胺注射液500μg,每日1次,肌肉注射,2组连续治疗21 d。观察2组患者的临床疗效和药物不良反应的发生情况,比较2组患者视网膜中央动脉收缩期峰值流速(PSV)、舒张末期流速(EDV)\正中神经的感觉传导速度(SCV)、运动传导速度(MCV)及血清血管生成素-2(Ang-2)、血管内皮细胞生长因子(VEGF)和8-异前列腺素F2α(8-iso-PGF2α)水平。结果治疗后,试验组和对照组总有效率差异有统计学意义(P<0.05)。治疗后试验组和对照组的PSV、EDV、SCV、MCV、Ang-2、VEGF、8-iso-PGF2α均较治疗前差异均有统计学意义(P<0.05),2组间比较差异有统计学意义(P<0.05)。试验组和对照组均未发现药物不良反应,安全性良好。结论甲钴胺联合前列地尔治疗DPN临床疗效显著,可改善患者PSV、EDV、SCV、MCV、Ang-2、VEGF及8-iso-PGF2α,且安全性良好。
Objective To determine the clinical effect and safety of mecobalamin and alprostadil in the treatment of diabetic peripheral neuropathy（DPN）,and to investigae its mechanism.Methods Ninety-four patients with DPN were randomly divided into the control group（n=47） and study group（n=47）.On the basis of routine treatment,the control group was given 10 μg qd Alprostadil by intravenous injection,and the study group was given 10 μg qd Alprostadil byintravenous injection＋500 μg qd Mecobalamin by intramuscular injection.The two groups received con-tinuous treatment for 21 d.The clinical effect and adverse drug reactions in the two groups were determined.The peak systolic velocity（PSV） and end diastolic velocity（EDV） of central retinal artery,sensory conduction velocity）（SCV） and motor conduction velocity（MCV） of median nerve,and the levels of serum angiogenin-2（Ang-2）,vascular endothelial cell growth factor（VEGF） and 8-iso-prostaglandin F2α（8-iso-PGF2α） in the two groups were compared.Results After thetreatment,the total effective rate in the study group and control group was statistically different（ P〈0.05）.After the treatment,the PSV,EDV,SCR,MCV,Ang-2,VEGF and 8-iso-PGF2α in the study group and control group were differences statistically（P〈0.05）.The study group and the control group showed no adverse drug reactions and good safety.Conclusion Mecobalamin and Alprostadil is significantly effective in the treatment of DPN,with good safety.
作者
吕慧慧
Lyu Huihui.(Department of Pharmacy, the First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou 310018, China)
出处
《中国药物与临床》
CAS
2018年第4期509-511,共3页
Chinese Remedies & Clinics
基金
高校博士学科点专项科研基金(20133322110002)
